An Open-Label, Phase I, Dose-Escalation Study Evaluating Two Dosing Schedules of PI3-Kinase Inhibitor (GDC-0941) in Patients With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable.
Phase of Trial: Phase I
Latest Information Update: 08 Jul 2016
At a glance
- Drugs Pictrelisib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Genentech
- 06 Jun 2016 Time frame of primary end point is given specifically which was previously given in broad term. Also no of arms changed from 1 to 3.
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Feb 2013 Planned end date changed from 1 Nov 2012 to 1 Apr 2014 as reported by ClinicalTrials.gov.